Physician profile
Julia Raber
NPI 1205800760
$489.92
in general payments reported to CMS, 2019-2025
11 companies · $139 in 2025
The $139 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2023: $28.85 · 2024: $196 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.76 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $126.16 | 2019 | |
| Astellas Pharma US INC | $117.01 | 2024 | Veozah |
| Novo Nordisk INC | $67.92 | 2025 | Wegovy |
| Mayne Pharma Commercial LLC | $35.03 | 2024 | |
| Sumitomo Pharma America, INC. | $28.85 | 2023 | Myfembree |
| Abbvie INC. | $23.25 | 2024 | |
| Hologic Sales and Service, LLC | $22.44 | 2025 | Novasure |
| Organon LLC | $20.49 | 2024 | |
| Kestra Medical Technology Services, INC. | $19.98 | 2025 | Assure Wcd |
| Lilly USA, LLC | $14.72 | 2025 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $14.07 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Raber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.